Danel (Adir Yeoshua) Ltd (DANE) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Danel (Adir Yeoshua) Ltd ILS 412, price ILS 429, upside -3.9%, quality 67 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Danel (Adir Yeoshua) Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 198.37 ILA – 670.58 ILA · fair‑value band 289.73 ILA – 514.73 ILA · the 428.60 ILA price screens above the 411.78 ILA fair value. Dashed = 300-day average. As of Sep 24, 2026.
Follow Danel (Adir Yeoshua) in your weekly email
Every Wednesday you see whether Danel (Adir Yeoshua) is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Danel (Adir Yeoshua) Ltd provides human resources services in Israel.
Show more
Danel (Adir Yeoshua) Ltd provides human resources services in Israel. The company provides recruitment, placement, and employment services in the areas of finance, insurance, administration, senior management, high-tech, biotech, cleantech, as well as outsourcing project management services, technological employee employment services, and occupational and computerized diagnostic services; payroll services; and nursing and medical services to disabled seniors, ministry of defense beneficiaries, and others. It also manages and operates dormitories and hostels, schools, rehabilitation and therapeutic day centers; and provides Referrals to special schools for complex populations, such as multisystemic learning disabilities, moderate-low functioning autism, intellectual disabilities, mental/emotional difficulties, and behavioral disorders. In addition, the company provides medical services, including surgical activities in ophthalmology field. Danel (Adir Yeoshua) Ltd was incorporated in 1974 and is based in Ramat Gan, Israel.
Stock analysis
Danel (Adir Yeoshua) Ltd (DANE) currently trades at 428.60 ILA, while our model-based Fair Value estimate is 411.78 ILA, implying the stock looks roughly 4.1% fairly valued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 485.71 ILA per share, and 13 of the 26 models we run sit above the 428.60 ILA price.
Bear case: the Asset-Based group reads lowest at 57.02 ILA, and 13 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: 289.73 ILA (bear) to 514.73 ILA (bull), the price of 428.60 ILA sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 67/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Danel (Adir Yeoshua) Ltd reported revenue of 2.9B ILS in FY2025 versus 2.3B ILS in FY2021, a compound +6.1%/yr. Reported net income was 117M ILS in FY2025, compounding −9.5%/yr from FY2021.
Key figures
Market cap 2.7B ILA · P/E ratio 17.4 · P/S ratio 0.70 · EPS (TTM) 24.61 ILA · Dividend yield 5.1% · Net margin 4.0% · Return on equity 28.4% · Return on assets (EBIT) 13.3%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).
What moves the price
The share trades about 18% below its 52-week high and 4% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 35% fair-value upside, at −4%, DANE screens richer than that median.
Fair Value models
Bear 289.73 ILAFair Value 411.78 ILABull 514.73 ILA
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (1.93 ILS per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.76/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+4.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.9%
Start year 2020 (pandemic). Over 10 years: +10.4% a year
Revenue growth 21 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: EBIT basis.
≈ +5.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+0.2%
Dividend (yield on the price)5.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−4% vs 5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 7%
Start year 2020 (pandemic)
⚠ Rate on operating basis: 2025 sits 63% above its own trend.
Growth Forecast
Price in line with expectations
The price assumes about as much growth as the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+10.2%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Israel: IMF forecast 2.1% a year to 2030, 1.7% from 2016 to 2025) that is about +7.9% a year for the price.
Compare Danel (Adir Yeoshua) Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 257 stocks
Beats the industry median on 8/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score67 · Top 25%
Fair Value upside−4% · Below median
Profitability
Return on equity (TTM)28% · Top 25%
Return on assets9% · Top 25%
Net margin (TTM)4% · Below median
Operating margin (TTM)8% · Below median
Growth and dividend
Revenue growth4% · Below median
Dividend yield (TTM)5.1% · Top 25%
Balance sheet
Debt / equity0.07× · Below median
Valuation Multiplesvs Medical Care Facilities median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Danel (Adir Yeoshua) Ltd (DANE) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 411.78 ILA versus a price of 428.60 ILA, about −4% upside (fairly valued).
What is the fair value of DANE?
Our model-based fair value for Danel (Adir Yeoshua) Ltd is 411.78 ILA (as of Sep 24, 2026), built from audited fundamentals. The current price: 428.60 ILA.
What is the quality score of DANE?
Danel (Adir Yeoshua) Ltd has a Quality Score of 67/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Danel (Adir Yeoshua) Ltd (DANE)?
Our model-based price target is the fair value of 411.78 ILA (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 289.73 ILA, optimistic scenario 514.73 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Danel (Adir Yeoshua) Ltd stock forecast for 2026?
Our models put fair value at 411.78 ILA, about −4% upside versus a price of 428.60 ILA (fairly valued). Cautious scenario 289.73 ILA, optimistic scenario 514.73 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of Danel (Adir Yeoshua) Ltd (DANE)?
Danel (Adir Yeoshua) Ltd reported trailing-twelve-month revenue of about 2.9B ILS (latest available figure, as of Sep 24, 2026).
Does Danel (Adir Yeoshua) Ltd pay a dividend?
Danel (Adir Yeoshua) Ltd currently shows a dividend yield of about 5.13% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Danel (Adir Yeoshua) Ltd (DANE)?
For today's price to be fair in a discounted-cash-flow model, Danel (Adir Yeoshua) Ltd would have to grow free cash flow by +10.2 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.9 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of DANE use?
Our models discount Danel (Adir Yeoshua) Ltd at 11.6 %: a base by market capitalisation (small), damped by beta 0.00, country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Danel (Adir Yeoshua) Ltd that is +10.2 % per year a year over ten years, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Danel (Adir Yeoshua) Ltd (DANE) delivered so far?
Over the past 5 years revenue at Danel (Adir Yeoshua) Ltd grew +7.9 % a year. The price currently implies +10.2 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Danel (Adir Yeoshua) Ltd (DANE) growing?
The median revenue growth in the sector is +4.7 % a year. That is the yardstick for the growth priced into Danel (Adir Yeoshua) Ltd (+10.2 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Danel (Adir Yeoshua) Ltd (DANE)?
The free-cash-flow yield on the price is 5.77 %: that much free cash flow Danel (Adir Yeoshua) Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Danel (Adir Yeoshua) Ltd (DANE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Danel (Adir Yeoshua) Ltd it is 411.78 ILA per share (as of Sep 24, 2026), against a price of 428.60 ILA. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Danel (Adir Yeoshua) Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, DANE trades above its calculated fair value: price 428.60 ILA, fair value 411.78 ILA, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DANE?
No. The price is what the market pays today (428.60 ILA); the fair value is what the company's own numbers justify (411.78 ILA). For Danel (Adir Yeoshua) Ltd the two are 16.82 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Danel (Adir Yeoshua) Ltd worth?
The market values Danel (Adir Yeoshua) Ltd at about 2.7B ILA (market capitalisation, as of Sep 24, 2026). Per share that is 428.60 ILA; our models calculate a fair value of 411.78 ILA per share.
What do the bullish and bearish scenarios say about DANE?
Our models span a range for Danel (Adir Yeoshua) Ltd: cautious scenario 289.73 ILA, base 411.78 ILA, optimistic 514.73 ILA per share (as of Sep 24, 2026, price 428.60 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DANE?
Danel (Adir Yeoshua) Ltd trades at a price-to-earnings ratio of 17.4 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 411.78 ILA is built from several models across several years. Other multiples: P/B 1.8, P/S 0.3, EV/EBITDA 2.9.
How solid is the balance sheet of Danel (Adir Yeoshua) Ltd (DANE)?
Balance-sheet figures for Danel (Adir Yeoshua) Ltd (as of Sep 24, 2026): return on equity 28.4%, debt of 0.07 per unit of equity. They feed the Quality Score of 67/100, which measures business quality independently of the share price.
How far is DANE from its 52-week high?
Danel (Adir Yeoshua) Ltd trades at 428.60 ILA, about 18% below its 52-week high of 521.98 ILA and 4% above the low of 413.40 ILA (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 411.78 ILA is for.
Which stocks are comparable to Danel (Adir Yeoshua) Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, IHH Healthcare Berhad, an investment holding company,, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Danel (Adir Yeoshua) Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 428.60 ILA, calculated fair value 411.78 ILA (−4%), Quality Score 67/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DANE calculated?
We run Danel (Adir Yeoshua) Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 411.78 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.1 % above its aggregate fair value. Danel (Adir Yeoshua) Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Danel (Adir Yeoshua) Ltd (DANE)?
The closing price on Sep 23, 2026 was 428.60 ILA. Our model-based fair value is 411.78 ILA, about −4% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Danel (Adir Yeoshua) Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the upper half of our model range, so the margin of safety is thin. The data supports the verdict: every model runs on fully documented inputs.
Where does the earnings growth of Danel (Adir Yeoshua) Ltd (DANE) come from?
Earnings per share at Danel (Adir Yeoshua) Ltd grew +0.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +8.0 %, EBIT margin +0.2 %, tax rate −2.5 %, residual (interest, one-offs) −5.3 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Danel (Adir Yeoshua) Ltd
How large is the market capitalisation of Danel (Adir Yeoshua) Ltd (DANE)?
The market capitalisation of Danel (Adir Yeoshua) Ltd is 2.7B ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Danel (Adir Yeoshua) Ltd (DANE)?
The price-to-sales ratio of Danel (Adir Yeoshua) Ltd is 0.70 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Danel (Adir Yeoshua) Ltd (DANE)?
Earnings per share at Danel (Adir Yeoshua) Ltd are 24.61 ILA (price ÷ EPS = P/E 17.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Danel (Adir Yeoshua) Ltd (DANE)?
The dividend yield of Danel (Adir Yeoshua) Ltd is 5.1% (payout 89.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Danel (Adir Yeoshua) Ltd (DANE)?
The net margin of Danel (Adir Yeoshua) Ltd is 4.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Danel (Adir Yeoshua) Ltd (DANE)?
The return on equity (ROE) of Danel (Adir Yeoshua) Ltd is 28.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Danel (Adir Yeoshua) Ltd (DANE)?
On an EBIT basis the return on assets of Danel (Adir Yeoshua) Ltd is 13.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Danel (Adir Yeoshua) Ltd (DANE)?
The operating margin of Danel (Adir Yeoshua) Ltd is 8.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Danel (Adir Yeoshua) Ltd (DANE)?
Revenue at Danel (Adir Yeoshua) Ltd is growing +3.7% versus a year earlier (3y avg +7.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Danel (Adir Yeoshua) Ltd (DANE)?
Earnings per share at Danel (Adir Yeoshua) Ltd are growing +31.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Danel (Adir Yeoshua) Ltd (DANE) carry?
The net debt of Danel (Adir Yeoshua) Ltd is 113M ILA (fiscal year 2025, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Danel (Adir Yeoshua) Ltd in the live analysis
One click puts Danel (Adir Yeoshua) Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
